Mattias Hammarström

About me
Publications
CV
Public outreach and news

About me

Head of Operations
Karma project
/ Doctoral student

Articles

Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2024;:djae280
Influence of endoxifen on mammographic density: results from the KARISMA-Tam trial
Hammarstrom M; Gabrielson M; Bergqvist J; Lundholm C; Crippa A; Backlund M; Wengstrom Y; Borgquist S; Eliasson E; Eriksson M; Tapia J; Czene K; Hall P
Article: INTERNATIONAL JOURNAL OF CANCER. 2024;155(2):339-351
Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change
Gabrielson M; Hammarstroem M; Bergqvist J; Lang K; Rosendahl AH; Borgquist S; Hellgren R; Czene K; Hall P
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2023;115(11):1310-1317
Prediction of breast cancer risk for sisters of women attending screening
Mao X; He W; Eriksson M; Lindstroem LS; Holowko N; Bajalica-Lagercrantz S; Hammarstrom M; Grassmann F; Humphreys K; Easton D; Hall P; Czene K
Article: BRITISH JOURNAL OF CANCER. 2023;129(1):61-71
Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women
Hammarstroem M; Gabrielson M; Crippa A; Discacciati A; Eklund M; Lundholm C; Baecklund M; Wengstroem Y; Borgquist S; Bergqvist J; Eriksson M; Tapia J; Czene K; Hall P
Article: INTERNATIONAL JOURNAL OF CANCER. 2023;152(11):2362-2372
Effects of tamoxifen on normal breast tissue histological composition: Results from a randomised six-arm placebo-controlled trial in healthy women
Gabrielson M; Hammarstrom M; Baecklund M; Bergqvist J; Lang K; Rosendahl AH; Borgquist S; Hellgren R; Czene K; Hall P
Article: ONCOLOGIST. 2022;27(7):E601-E603
Time to Mammographic Density Decrease After Exposure to Tamoxifen
Backlund M; Eriksson M; Hammarstrom M; Thoren L; Bergqvist J; Margolin S; Hellgren R; Wengstrom Y; Gabrielson M; Czene K; Hall P
Article: ONCOLOGIST. 2022;27(7):E597-E600
Topical Endoxifen for Mammographic Density Reduction-A Randomized Controlled Trial
Backlund M; Eriksson M; Gabrielson M; Hammarstrom M; Quay S; Bergqvist J; Hellgren R; Czene K; Hall P
Article: ANNALS OF ONCOLOGY. 2021;32(10):1286-1293
CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial
He W; Eriksson M; Eliasson E; Grassmann F; Backlund M; Gabrielson M; Hammarstrom M; Margolin S; Thoren L; Wengstrom Y; Borgquist S; Hall P; Czene K
Article: LAKARTIDNINGEN. 2021;118:21092
[It is time for individual breast cancer prevention].
Hall P; Hammarström M; Hellgren R
Article: JOURNAL OF CLINICAL ONCOLOGY. 2021;39(17):1899-1908
Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial
Eriksson M; Eklund M; Borgquist S; Hellgren R; Margolin S; Thoren L; Rosendahl A; Lang K; Tapia J; Backlund M; Discacciati A; Crippa A; Gabrielson M; Hammarstrom M; Wengstrom Y; Czene K; Hall AP
Article: BMC CANCER. 2020;20(1):247
European women's perceptions of the implementation and organisation of risk-based breast cancer screening and prevention: a qualitative study
Rainey L; van der Waal D; Jervaeus A; Donnelly LS; Evans DG; Hammarstrom M; Hall P; Wengstrom Y; Broeders MJM
Article: PSYCHO-ONCOLOGY. 2019;28(5):1056-1062
Women's perceptions of personalized risk-based breast cancer screening and prevention: An international focus group study
Rainey L; Jervaeus A; Donnelly LS; Evans DG; Hammarstrom M; Hall P; Wengstrom Y; Broeders MJM; van der Waal D
Article: INTERNATIONAL JOURNAL OF EPIDEMIOLOGY. 2017;46(6):1740-1741g
Cohort Profile: The Karolinska Mammography Project for Risk Prediction of Breast Cancer (KARMA)
Gabrielson M; Eriksson M; Hammarstrom M; Borgquist S; Leifland K; Czene K; Hall P

Employments

Team Manager, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 2022-
Phd Student, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 2019-2025

About me

Articles

Employments

News from KI

Events from KI